162 related articles for article (PubMed ID: 10494961)
21. Mathematical model of influenza A virus production in large-scale microcarrier culture.
Möhler L; Flockerzi D; Sann H; Reichl U
Biotechnol Bioeng; 2005 Apr; 90(1):46-58. PubMed ID: 15736163
[TBL] [Abstract][Full Text] [Related]
22. Production of influenza virus in serum-free mammalian cell cultures.
Merten OW; Manuguerra JC; Hannoun C; van der Werf S
Dev Biol Stand; 1999; 98():23-37; discussion 73-4. PubMed ID: 10494957
[TBL] [Abstract][Full Text] [Related]
23. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.
Kobasa D; Takada A; Shinya K; Hatta M; Halfmann P; Theriault S; Suzuki H; Nishimura H; Mitamura K; Sugaya N; Usui T; Murata T; Maeda Y; Watanabe S; Suresh M; Suzuki T; Suzuki Y; Feldmann H; Kawaoka Y
Nature; 2004 Oct; 431(7009):703-7. PubMed ID: 15470432
[TBL] [Abstract][Full Text] [Related]
24. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases.
Smith KA; Colvin CJ; Weber PS; Spatz SJ; Coussens PM
Vaccine; 2008 Jul; 26(29-30):3778-82. PubMed ID: 18524432
[TBL] [Abstract][Full Text] [Related]
25. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
[TBL] [Abstract][Full Text] [Related]
26. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.
Horimoto T; Takada A; Fujii K; Goto H; Hatta M; Watanabe S; Iwatsuki-Horimoto K; Ito M; Tagawa-Sakai Y; Yamada S; Ito H; Ito T; Imai M; Itamura S; Odagiri T; Tashiro M; Lim W; Guan Y; Peiris M; Kawaoka Y
Vaccine; 2006 Apr; 24(17):3669-76. PubMed ID: 16378663
[TBL] [Abstract][Full Text] [Related]
27. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
[TBL] [Abstract][Full Text] [Related]
28. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation.
Saito T; Nakaya Y; Suzuki T; Ito R; Saito T; Saito H; Takao S; Sahara K; Odagiri T; Murata T; Usui T; Suzuki Y; Tashiro M
J Med Virol; 2004 Oct; 74(2):336-43. PubMed ID: 15332284
[TBL] [Abstract][Full Text] [Related]
29. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition.
Böttcher E; Freuer C; Steinmetzer T; Klenk HD; Garten W
Vaccine; 2009 Oct; 27(45):6324-9. PubMed ID: 19840668
[TBL] [Abstract][Full Text] [Related]
30. Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation.
Gubareva LV; Wood JM; Meyer WJ; Katz JM; Robertson JS; Major D; Webster RG
Virology; 1994 Feb; 199(1):89-97. PubMed ID: 8116258
[TBL] [Abstract][Full Text] [Related]
31. Reassortment and modification of hemagglutinin cleavage motif of avian/WSN influenza viruses generated by reverse genetics that correlate with attenuation.
Lu JH; Long JX; Jia LJ; Liu YL; Shao WX; Zhang YM; Liu XF
Acta Virol; 2006; 50(4):243-9. PubMed ID: 17177609
[TBL] [Abstract][Full Text] [Related]
32. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production.
Coussens PM; Smith KA; Weber PS; Colvin CJ
Vaccine; 2011 Nov; 29(47):8661-8. PubMed ID: 21911025
[TBL] [Abstract][Full Text] [Related]
33. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine.
Ghendon YZ; Markushin SG; Akopova II; Koptiaeva IB; Nechaeva EA; Mazurkova LA; Radaeva IF; Kolokoltseva TD
Vaccine; 2005 Sep; 23(38):4678-84. PubMed ID: 16026905
[TBL] [Abstract][Full Text] [Related]
34. Deviation from the random distribution pattern of influenza A virus gene segments in reassortants produced under non-selective conditions.
Varich NL; Gitelman AK; Shilov AA; Smirnov YA; Kaverin NV
Arch Virol; 2008; 153(6):1149-54. PubMed ID: 18414973
[TBL] [Abstract][Full Text] [Related]
35. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
[TBL] [Abstract][Full Text] [Related]
36. Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005.
Tsai HP; Wang HC; Kiang D; Huang SW; Kuo PH; Liu CC; Su IJ; Wang JR
J Clin Microbiol; 2006 Aug; 44(8):2705-13. PubMed ID: 16891481
[TBL] [Abstract][Full Text] [Related]
37. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK).
Oxford JS; Corcoran T; Knott R; Bates J; Bartolomei O; Major D; Newman RW; Yates P; Robertson J; Webster RG
Bull World Health Organ; 1987; 65(2):181-7. PubMed ID: 3496984
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of chicken-origin (DF-1) and quail-origin (QT-6) fibroblast cell lines for replication of avian influenza viruses.
Lee CW; Jung K; Jadhao SJ; Suarez DL
J Virol Methods; 2008 Oct; 153(1):22-8. PubMed ID: 18638503
[TBL] [Abstract][Full Text] [Related]
39. Maturation efficiency of viral glycoproteins in the ER impacts the production of influenza A virus.
Ueda M; Yamate M; Du A; Daidoji T; Okuno Y; Ikuta K; Nakaya T
Virus Res; 2008 Sep; 136(1-2):91-7. PubMed ID: 18550190
[TBL] [Abstract][Full Text] [Related]
40. Reassortment and evolution of current human influenza A and B viruses.
Xu X; Lindstrom SE; Shaw MW; Smith CB; Hall HE; Mungall BA; Subbarao K; Cox NJ; Klimov A
Virus Res; 2004 Jul; 103(1-2):55-60. PubMed ID: 15163489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
